Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
Ticker Information
Ticker
CURXCompany Name
CURANEX PHARMACEUTICALS INCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQCURANEX PHARMACEUTICALS INC - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
CURX - EBITDA Historical data
| Date | Depreciation, Amortization & Accretion | Earning Before Interest & Taxes (EBIT) | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) |
|---|---|---|---|
| 12/31/2024 | $ 0 | $ -361.51K | $ -361.51K |
| 12/31/2023 | $ 1.81K | $ -19.2K | $ -17.38K |
Key Performance Insights, Last 5 Years
- CURANEX PHARMACEUTICALS INC's latest trailing twelve months (TTM) EBITDA stands at $ -17.38K.
- Over the past 5 years, CURANEX PHARMACEUTICALS INC's average EBITDA has been $ -189.44K.
- The median EBITDA for CURANEX PHARMACEUTICALS INC during this period was $ -189.44K
- CURANEX PHARMACEUTICALS INC reached its highest EBITDA over the past 5 years at $ -17.38K.
- The lowest EBITDA recorded by CURANEX PHARMACEUTICALS INC in the same timeframe $ -361.51K
CURANEX PHARMACEUTICALS INC's EBITDA vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
EBITDA Benchmarks
Similar metrics to EBITDA:
- Depreciation, Amortization & Accretion - [Cash Flow Statement] A component of operating cash flow [NCFO] representing the aggregate net amount of depreciation, amortization, and accretion recognized during an accounting period. As a non-cash item, the net amount is added back to net income when calculating cash provided by operations.
- Enterprise Value over EBITDA - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].
- EBITDA per Share - [Calculation] The amount of earnings before interest, taxes, depreciation, and amortization attributed to each share, calculated as [EBITDA] divided by the weighted average number of shares [SharesWA] after adjusting for [ShareFactor].
- Earning Before Interest & Taxes (EBIT) - [Income Statement] Earnings before interest and taxes measures a company's net income [NetInc] prior to the deduction of interest [IntExp] and tax expenses [TaxExp].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
Definition of Earnings Before Interest Taxes & Depreciation Amortization (EBITDA)
[Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].EBIT + DepAmor
(=) EBITDA EBITDA for CURANEX PHARMACEUTICALS INC is calculated as follows: EBIT [ $ -19.2K ] + DepAmor [ $ 1.81K ]
(=) EBITDA [ $ -17.38K ] CURX - Earnings Before Interest Taxes & Depreciation Amortization (EBITDA), Last 5 years
$ -361.51K
Minimum
Dec 31, 2024
$ -17.38K
Maximum
Dec 31, 2023
$ -189.44K
Average
$ -189.44K
Median
EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EBITDA for companies in the Total Stock Market. The average EBITDA of the companies is $ 58.77M with a standard deviation of $ 166.95M.
The following table provides additional summary stats:
EBITDA in the Market:
| filtered constituents | 3.25K |
|---|---|
| min | $ -493.3M |
| max | $ 590.6M |
| average | $ 58.77M |
| median | $ 8.83M |
| std | $ 166.95M |